FDA approves Teva’s digital COPD, asthma inhaler

December 26, 2018

Teva (NYSE:TEVA) said this week that the FDA approved its ProAir Digihaler device – a digital inhaler that uses sensors to connect to a companion mobile app for people with asthma and chronic obstructive pulmonary disease.

The company’s device features built-in sensors that can measure inspiratory flow and detect when the inhaler is used. After the data is sent to a mobile app, the user can review historical data and share it with their healthcare professionals.

Read More on Mass Device